Edinburgh-based biotech Invizius has successfully raised £950,000 in a funding round led by Mercia Ventures. This investment will accelerate the clinical trials of their innovative H-Guard product, aimed at improving the lives of dialysis patients.
- Funding Details: The recent funding brings Invizius’s total to over £13 million, with contributions from Mercia Ventures, Calculus Capital, Syensqo, and others.
- H-Guard Product: Designed to address inflammatory responses during dialysis, H-Guard coats machine surfaces to prevent immune reactions that can cause severe complications.
- Clinical Progress: A recent ‘First in Human’ study showed promising safety and tolerability, paving the way for further trials.
- Company Background: Founded in 2018 as a spin-out from the University of Edinburgh, Invizius aims to improve patient dialysis outcomes.
The continued support from investors and promising trial results position Invizius to significantly advance dialysis treatment, ultimately enhancing patient care and outcomes.
